Evidence map›Paper›PMID 40979982›Full record

ArticleEuropean heart journal supplements : journal of the European Society of Cardiology2025

May Measurement Month 2022: an analysis of blood pressure screening results from China.

Xin-Yu Wang, Zhe Hu, Chang-Yuan Liu, Cheng-Bao Lei, Qi-Dong Zheng, Mei-Sheng Zheng, Xiao-Rui Chen, Li-Bin Ge, Thomas Beaney, Gabriele Kerr and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European heart journal supplements : journal of the European Society of Cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Xin-Yu WangDepartment of Cardiovascular Medicine, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Ruijin 2nd Road 197, Shanghai 200025, Shanghai, China.
Zhe HuDepartment of Cardiovascular Medicine, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Ruijin 2nd Road 197, Shanghai 200025, Shanghai, China.
Chang-Yuan LiuDepartment of Cardiovascular Medicine, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Ruijin 2nd Road 197, Shanghai 200025, Shanghai, China.
Cheng-Bao LeiDepartment of Geriatrics, Sinopharm Tongmei General Hospital, 1 Seventh Wei Road, Xinpingwang Miner Area, Datong 037003, Shanxi Province, China.
Qi-Dong ZhengDepartment of Internal Medicine, The Second People's Hospital of Yuhuan, No. 77, Middle Huanbao Road, Chumen Town, Yuhuan 317605, Zhejiang Province, China.
Mei-Sheng ZhengHypertension Diagnosis and Treatment Center, Wuhu Traditional Chinese Medical Hospital, No. 430, Jiuhua South Road, Wuhu 241003, Anhui Province, China.
Xiao-Rui ChenDepartment of Cardiovascular Medicine, Nanyang City First People's Hospital, No. 12, Renmin Road, Nanyang 473010, Henan Province, China.
Li-Bin GeGeneral practice, Huangdu Community Health Service Center, No. 10 Xinhuang Road, Jiading District, Shanghai 201804, Shanghai, China.
Thomas BeaneyImperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, London W12 7RH, UK.ORCID https://orcid.org/0000-0001-9709-7264
Gabriele KerrImperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, London W12 7RH, UK.
Neil R PoulterImperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, London W12 7RH, UK.
Yan LiDepartment of Cardiovascular Medicine, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Ruijin 2nd Road 197, Shanghai 200025, Shanghai, China.
Xin ChenDepartment of Cardiovascular Medicine, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Ruijin 2nd Road 197, Shanghai 200025, Shanghai, China.
Ji-Guang WangDepartment of Cardiovascular Medicine, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Ruijin 2nd Road 197, Shanghai 200025, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The May Measurement Month (MMM) campaign was carried out in China in 2022 with the aim of raising awareness of raised blood pressure (BP). Here, we report the findings of the campaign. Adults aged ≥18 years were recruited opportunistically at 30 China provinces. Three seated BP readings were taken for each participant, along with completion of a questionnaire on demographics, lifestyle factors, and comorbidities. Hypertension was defined as a systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg or being on antihypertensive medication. Controlled BP was defined as being on antihypertensive medication with a BP <140/90 mmHg. Multiple imputation was used to estimate any missing BP readings. In total, 188 975 were screened, with a mean age of 46.0 years, and 49.6% of whom were female. Of all participants, 49 788 (26.3%) had hypertension, of whom 11 268 (22.6%) were aware, and 10 945 (22.0%) were on antihypertensive medication. Of those on antihypertensive medication, 6362 (58.1%) had controlled BP, and of all participants with hypertension, 12.8% had controlled BP. After adjustment for age, sex, and use of antihypertensive medication, both systolic and diastolic BP were significantly (

Indexed as

Blood PressureControlHypertensionScreeningTreatment

Identifiers

PMID40979982
PMCPMC12449216

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.